Hosted on MSN
Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M
President and CEO Eric Dube emphasized "exceptional progress across our three key priorities: delivering strong commercial execution in IgA nephropathy, preparing for a potential FDA approval in FSGS, ...
The last time I posted on Travere Therapeutics (TVTX), in September 2025, I gave the stock a buy rating. I was discussing the fact that the FDA had opted not to convene an Advisory Committee meeting ...
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s strong growth in IgAN and recent FSGS approval. TVTX’s premium valuation is justified by rapid ...
Travere TherapeuticsTVTX is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone following a big earnings gap-up and a new approval for its bread-and-butter drug, Filspari. Filspari ...
Travere cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or Travere’s common stock. J.P. Morgan, Jefferies, and Leerink Partners are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results